nach oben

Inflammation Research

Erschienen in:

14.08.2020 | Review

Metabolic reprogramming as a key regulator in the pathogenesis of rheumatoid arthritis

verfasst von: Wei-wei Cai, Yun Yu, Shi-ye Zong, Fang Wei

Erschienen in: Inflammation Research | Ausgabe 11/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Rheumatoid arthritis (RA) is a chronic, systemic autoimmune disease with synovitis as pathological changes. The immune microenvironment of RA promotes metabolic reprogramming of immune cells and stromal cells, which leads to dysfunction and imbalance of immune homeostasis. Cell metabolism undergoes the switch from a static regulatory state to a highly metabolic active state, which changes the redox-sensitive signaling pathway and also leads to the accumulation of metabolic intermediates, which in turn can act as signaling molecules and further aggravate the inflammatory response. The reprogramming of immunometabolism affects the function of immune cells and is crucial to the pathogenesis of RA. In addition, mitochondrial dysfunction plays a key role in glycolytic reprogramming in RA. These metabolic changes may be potential therapeutic targets for RA. Therefore, we reviewed the metabolic reprogramming of RA immune cells and fibroblast-like synovium cells (FLS) and its relationship with mitochondrial dysfunction.

Methods

A computer-based online search was performed using the PubMed database and Web of Science database for published articles concerning immunometabolic reprogramming, mitochondrial dysfunction, and rheumatoid arthritis.

Results

This article reviews the metabolic reprogramming of immune cells and fibroblast-like synoviocytes in RA and their relationship to mitochondrial disfunction, as well as the key pro-inflammatory pathways associated with metabolic reprogramming and chemotherapy as a potential future therapeutic strategy for RA.

Yap H-Y, Tee SZ-Y, Wong MM-T, Chow S-K, Peh S-C, Teow S-Y. Pathogenic role of immune cells in rheumatoid arthritis: implications in clinical treatment and biomarker development[J]. Cells. 2018;7:10.

Alvandpur N, Tabatabaei R, Tahamoli-Roudsari A, Basiri Z, Behzad M, Rezaeepoor M, et al. Circulating IFN-gamma producing CD4+ T cells and IL-1 7A producing CD4+ T cells, HLA-shared epitope and ACPA may characterize the clinical response to therapy in rheumatoid arthritis patients[J]. Hum Immunol. 2020

Morita T, Shima Y, Wing JB, Sakaguchi S, Ogata A, Kumanogoh A. The proportion of regulatory T cells in patients with rheumatoid arthritis: a meta-analysis[J]. PLoS ONE. 2016;11(9):e0162306.PubMedPubMedCentral

Hu X-X, Wu Y-j, Zhang J, Wei W. T-cells interact with B cells, dendritic cells, and fibroblast-like synoviocytes as hub-like key cells in rheumatoid arthritis[J]. Int Immunopharmacol. 2019;70:428–34.PubMed

Warburg O. On the origin of cancer cells[J]. Science. 1956;123(3191):309–14 (New York, N.Y.).PubMed

Fracchia KM, Walsh CM. Metabolic mysteries of the inflammatory response: T cell polarization and plasticity[J]. Int Rev Immunol. 2015;34(1):3–18.PubMed

Madeira VMC. Overview of mitochondrial bioenergetics[J]. Methods Mol Biol. 2018;1782:1–6.PubMed

Maldonado EN, Lemasters JJ. ATP/ADP ratio, the missed connection between mitochondria and the Warburg effect[J]. Mitochondrion. 2014;19:78–84.PubMed

Pearce EL, Pearce EJ. Metabolic pathways in immune cell activation and quiescence[J]. Immunity. 2013;38(4):633–43.PubMedPubMedCentral

10.

Stathopoulou C, Nikoleri D, Bertsias G. Immunometabolism: an overview and therapeutic prospects in autoimmune diseases[J]. Immunotherapy. 2019;11(9):813–29.PubMed

11.

Young SP, Kapoor SR, Viant MR, Byrne JJ, Filer A, Buckley CD, et al. The impact of inflammation on metabolomic profiles in patients with arthritis[J]. Arthritis Rheum. 2013;65(8):2015–23.PubMedPubMedCentral

12.

Okano T, Saegusa J, Nishimura K, Takahashi S, Sendo S, Ueda Y, et al. 3-bromopyruvate ameliorate autoimmune arthritis by modulating Th17/Treg cell differentiation and suppressing dendritic cell activation[J]. Sci Rep. 2017;7:42412.PubMedPubMedCentral

13.

Abboud G, Choi S-C, Kanda N, Zeumer-Spataro L, Roopenian DC, Morel L. Inhibition of glycolysis reduces disease severity in an autoimmune model of rheumatoid arthritis[J]. Front Immunol. 2018;9:1973.PubMedPubMedCentral

14.

Song G, Lu Q, Fan H, Zhang X, Ge L, Tian R, et al. Inhibition of hexokinases holds potential as treatment strategy for rheumatoid arthritis[J]. Arthritis Res Ther. 2019;21:87.PubMedPubMedCentral

15.

Kumar P, Yao LJ, Saidin S, Paleja B, Van Loosdregt J, Chua C, et al. Molecular mechanisms of autophagic memory in pathogenic T cells in human arthritis[J]. J Autoimmun. 2018;94:90–8.PubMed

16.

De Biasi S, Simone AM, Bianchini E, Lo Tartaro D, Pecorini S, Nasi M, et al. Mitochondrial functionality and metabolism in T cells from progressive multiple sclerosis patients[J]. Eur J Immunol. 2019;49:2204–21.PubMed

17.

Yzafhamsagjaw CM. Phosphofructokinase deficiency impairs ATP generation, autophagy, and redox balance in rheumatoid arthritis T cells[J]. J Exp Med. 2013;210(10):2119–344.

18.

Yang Z, Fujii H, Mohan SV, Goronzy JJ, Weyand CM. Phosphofructokinase deficiency impairs ATP generation, autophagy, and redox balance in rheumatoid arthritis T cells[J]. J Exp Med. 2013;210(10):2119–344.PubMedPubMedCentral

19.

Yang Z, Shen Y, Oishi H, Matteson EL, Tian L, Goronzy JJ, et al. Restoring oxidant signaling suppresses proarthritogenic T cell effector functions in rheumatoid arthritis[J]. Sci Transl Med. 2016;8(331):331ra38.PubMedPubMedCentral

20.

Akimoto M, Yunoue S, Otsubo H, Yoshitama T, Kodama K, Matsushita K, et al. Assessment of peripheral blood CD4+adenosine triphosphate activity in patients with rheumatoid arthritis[J]. Mod Rheumatol. 2013;23(1):19–27.PubMed

21.

Angiari S, Runtsch MC, Sutton CE, Palsson-McDermott EM, Kelly B, Rana N, et al. Pharmacological activation of pyruvate kinase M2 inhibits CD4(+) T cell pathogenicity and suppresses autoimmunity[J]. Cell Metabo. 2020;31(2):391.

22.

Kono M, Maeda K, Stocton-Gavanescu I, Pan W, Umeda M, Katsuyama E, et al. Pyruvate kinase M2 is requisite for Th1 and Th17 differentiation[J]. Jci Insight. 2019;4(12):1.

23.

Sauer H, Wartenberg M, Hescheler J. Reactive oxygen species as intracellular messengers during cell growth and differentiation[J]. Cell Physiol Biochem. 2001;11(4):173–86.PubMed

24.

Iyama T, Wilson DM III. DNA repair mechanisms in dividing and non-dividing cells[J]. DNA Repair. 2013;12(8):620–36.PubMedPubMedCentral

25.

Li Y, Shen Y, Hohensinner P, Ju J, Wen Z, Goodman SB, et al. Deficient activity of the nuclease MRE11A induces T cell aging and promotes arthritogenic effector functions in patients with rheumatoid arthritis[J]. Immunity. 2016;45(4):903–16.PubMedPubMedCentral

26.

Hajizadeh S, DeGroot J, TeKoppele JM, Tarkowski A, Collins LV. Extracellular mitochondrial DNA and oxidatively damaged DNA in synovial fluid of patients with rheumatoid arthritis[J]. Arthritis Res Ther. 2003;5(5):R234–R240240.PubMedPubMedCentral

27.

Nakahira K, Haspel JA, Rathinam VAK, Lee S-J, Dolinay T, Lam HC, et al. Autophagy proteins regulate innate immune responses by inhibiting the release of mitochondrial DNA mediated by the NALP3 inflammasome[J]. Nat Immunol. 2011;12(3):222–U257.PubMed

28.

Goetzl EJ, Falchuk KH, Zeiger LS, Sullivan AL, Hebert CL, Adams JP, et al. A physiological approach to the assessment of disease activity in rheumatoid arthritis[J]. J Clin Investig. 1971;50(6):1167–80.PubMed

29.

Maria Quinonez-Flores C, Aidee Gonzalez-Chavez S, Pacheco-Tena C. Hypoxia and its implications in rheumatoid arthritis[J]. J Biomed Sci. 2016;23:62.

30.

Hua S, Dias TH. Hypoxia-inducible factor (HIF) as a target for novel therapies in rheumatoid arthritis[J]. Front Pharmacol. 2016;7:184.PubMedPubMedCentral

31.

Shi LZ, Wang R, Huang G, Vogel P, Neale G, Green DR, et al. HIF1 alpha-dependent glycolytic pathway orchestrates a metabolic checkpoint for the differentiation of T(H)17 and T-reg cells[J]. J Exp Med. 2011;208(7):1367–76.PubMedPubMedCentral

32.

Haas R, Smith J, Rocher-Ros V, Nadkarni S, Montero-Melendez T, D'Acquisto F, et al. Lactate regulates metabolic and proinflammatory circuits in control of T cell migration and effector functions[J]. Plos Biol. 2015;13(7):e1002202.PubMedPubMedCentral

33.

Alvarez-Errico D, Vento-Tormo R, Ballestar E. Genetic and epigenetic determinants in autoinflammatory diseases[J]. Front Immunol. 2017;8:318.PubMedPubMedCentral

34.

Udalova IA, Mantovani A, Feldmann M. Macrophage heterogeneity in the context of rheumatoid arthritis[J]. Nat Rev Rheumatol. 2016;12(8):472–85.PubMed

35.

Rodrigues HM, Juengel A, Gay RE, Gay S. Innate immunity, epigenetics and autoimmunity in rheumatoid arthritis[J]. Mol Immunol. 2009;47(1):12–8.

36.

Di Benedetto P, Ruscitti P, Vadasz Z, Toubi E, Giacomelli R. Macrophages with regulatory functions, a possible new therapeutic perspective in autoimmune diseases[J]. Autoimmun Rev. 2019;18(10):102369.PubMed

37.

O'Neill LAJ, Pearce EJ. Immunometabolism governs dendritic cell and macrophage function[J]. J Exp Med. 2016;213(1):15–23.PubMedPubMedCentral

38.

Levi EH, Watad A, Whitby A, Tiosano S, Comaneshter D, Cohen AD, et al. Coexistence of ischemic heart disease and rheumatoid arthritis patients—a case control study[J]. Autoimmun Rev. 2016;15(4):393–6.

39.

Shirai T, Nazarewicz RR, Wallis BB, Yanes RE, Watanabe R, Hilhorst M, et al. The glycolytic enzyme PKM2 bridges metabolic and inflammatory dysfunction in coronary artery disease[J]. J Exp Med. 2016;213(3):337–54.PubMedPubMedCentral

40.

Gao X, Wang H, Yang JJ, Liu X, Liu Z-R. Pyruvate kinase M2 regulates gene transcription by acting as a protein kinase[J]. Mol Cell. 2012;45(5):598–609.PubMedPubMedCentral

41.

Yang P, Li Z, Li H, Lu Y, Wu H, Li Z. Pyruvate kinase M2 accelerates pro-inflammatory cytokine secretion and cell proliferation induced by lipopolysaccharide in colorectal cancer[J]. Cell Signal. 2015;27(7):1525–32.PubMed

42.

Yang P, Li Z, Fu R, Wu H, Li Z. Pyruvate kinase M2 facilitates colon cancer cell migration via the modulation of STAT3 signalling[J]. Cell Signal. 2014;26(9):1853–62.PubMed

43.

Kong Q, Li N, Cheng H, Zhang X, Cao X, Qi T, et al. HSPA12A is a novel player in nonalcoholic steatohepatitis via promoting nuclear PKM2-mediated M1 macrophage polarization[J]. Diabetes. 2019;68(2):361–76.PubMed

44.

Xu D, Liang J, Lin J, Yu C. PKM2: a potential regulator of rheumatoid arthritis via glycolytic and non-glycolytic pathways[J]. Front Immunol. 2019;10:2919.PubMedPubMedCentral

45.

Xu J, Jiang C, Wang X, Geng M, Peng Y, Guo Y, et al. Upregulated PKM2 in macrophages exacerbates experimental arthritis via STAT1 signaling[J]. Jo Immunol. 2020;205(1):181–92.

46.

Wilkinson LS, Pitsillides AA, Worrall JG, Edwards JC. Light microscopic characterization of the fibroblast-like synovial intimal cell (synoviocyte)[J]. Arthritis Rheum. 1992;35(10):1179–84.PubMed

47.

Smith MD. The normal synovium[J]. Open Rheumatol J. 2011;5:100–6.PubMedPubMedCentral

48.

Bottini N, Firestein GS. Duality of fibroblast-like synoviocytes in RA: passive responders and imprinted aggressors[J]. Nat Rev Rheumatol. 2013;9(1):24–33.PubMed

49.

Wang J-G, Xu W-D, Zhai W-T, Li Y, Hu J-W, Hu B, et al. Disorders in angiogenesis and redox pathways are main factors contributing to the progression of rheumatoid arthritis a comparative proteomics study[J]. Arthritis Rheum. 2012;64(4):993–1004.PubMed

50.

Takahashi S, Saegusa J, Sendo S, Okano T, Akashi K, Irino Y, et al. Glutaminase 1 plays a key role in the cell growth of fibroblast-like synoviocytes in rheumatoid arthritis[J]. Arthritis Res Ther. 2017;19:1–10.

51.

Ahn JK, Kim S, Hwang J, Kim J, Kim KH, Cha HS. GC/TOF-MS-based metabolomic profiling in cultured fibroblast-like synoviocytes from rheumatoid arthritis[J]. Jt Bone Spine. 2016;83(6):707–13.

52.

Biniecka M, Canavan M, McGarry T, Gao W, McCormick J, Cregan S, et al. Dysregulated bioenergetics: a key regulator of joint inflammation[J]. Ann Rheum Dis. 2016;75(12):2192–200.PubMedPubMedCentral

53.

de Oliveira PG, Farinon M, Sanchez-Lopez E, Miyamoto S, Guma M. Fibroblast-like synoviocytes glucose metabolism as a therapeutic target in rheumatoid arthritis[J]. Front Immunol. 2019;10:1743.PubMedPubMedCentral

54.

DeBerardinis RJ, Mancuso A, Daikhin E, Nissim I, Yudkoff M, Wehrli S, et al. Beyond aerobic glycolysis: Transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis[J]. Proc Natl Acad Sci USA. 2007;104(49):19345–50.PubMed

55.

Wellen KE, Lu C, Mancuso A, Lemons JMS, Ryczko M, Dennis JW, et al. The hexosamine biosynthetic pathway couples growth factor-induced glutamine uptake to glucose metabolism[J]. Genes Dev. 2010;24(24):2784–99.PubMedPubMedCentral

56.

Warburg O, Wind F, Negelein E. The metabolism of tumors in the body[J]. J Gen Physiol. 1927;8(6):519–30.PubMedPubMedCentral

57.

Wise DR, Thompson CB. Glutamine addiction: a new therapeutic target in cancer[J]. Trends Biochem Sci. 2010;35(8):427–33.PubMedPubMedCentral

58.

Schapira AHV. Mitochondrial disease[J]. Lancet. 2006;368(9529):70–82.PubMed

59.

Taylor RW, Turnbull DM. Mitochondrial DNA mutations in human disease[J]. Nat Rev Genet. 2005;6(5):389–402.PubMedPubMedCentral

60.

Schumacker PT, Gillespie MN, Nakahira K, Choi AMK, Crouser ED, Piantadosi CA, et al. Mitochondria in lung biology and pathology: more than just a powerhouse[J]. Am J Physiol Lung Cell Mol Physiol. 2014;306(11):L962–L974974.PubMedPubMedCentral

61.

Weyand CM, Goronzy JJ. Immunometabolism in early and late stages of rheumatoid arthritis[J]. Nat Rev Rheumatol. 2017;13(5):1–11.

62.

Weyand CM, Zeisbrich M, Goronzy JJ. Metabolic signatures of T-cells and macrophages in rheumatoid arthritis[J]. Curr Opin Immunol. 2017;46:112–20.PubMedPubMedCentral

63.

Fearon U, Canavan M, Biniecka M, Veale DJ. Hypoxia, mitochondrial dysfunction and synovial invasiveness in rheumatoid arthritis[J]. Nat Rev Rheumatol. 2016;12(7):385–97.PubMed

64.

Rongvaux A. Innate immunity and tolerance toward mitochondria[J]. Mitochondrion. 2018;41:14–20.PubMed

65.

Filippin LI, Vercelino R, Marroni NP, Xavier RM. Redox signalling and the inflammatory response in rheumatoid arthritis[J]. Clin Exp Immunol. 2008;152(3):415–22.PubMedPubMedCentral

66.

Chan DC. Mitochondria: dynamic organelles in disease, aging, and development[J]. Cell. 2006;125(7):1241–52.PubMed

67.

Tilokani L, Nagashima S, Paupe V, Prudent J. Mitochondrial dynamics: overview of molecular mechanisms. Mitochondrial Dis. 2018;62:341–60.

68.

Dorn GW II. Evolving concepts of mitochondrial dynamics. Annu Rev Physiol. 2019;81:1–17.PubMed

69.

Rambold AS, Pearce EL. Mitochondrial dynamics at the interface of immune cell metabolism and function[J]. Trends Immunol. 2018;39(1):6–18.PubMed

70.

Wang X, Chen Z, Fan X, Li W, Qu J, Dong C, et al. Inhibition of DNM1L and mitochondrial fission attenuates inflammatory response in fibroblast-like synoviocytes of rheumatoid arthritis[J]. J Cell Mol Med. 2020;24(2):1516–28.PubMed

71.

D'Souza AD, Parikh N, Kaech SM, Shadel GS. Convergence of multiple signaling pathways is required to coordinately up-regulate mtDNA and mitochondrial biogenesis during T cell activation[J]. Mitochondrion. 2007;7(6):374–85.PubMedPubMedCentral

72.

Buck MD, O'Sullivan D, Geltink RIK, Curtis JD, Chang C-H, Sanin DE, et al. Mitochondrial dynamics controls T cell fate through metabolic programming[J]. Cell. 2016;166(1):63–766.PubMedPubMedCentral

73.

O'Sullivan D, van der Windt GJW, Huang SC-C, Curtis JD, Chang C-H, Buck MD, et al. Memory CD8(+) T cells use cell-intrinsic lipolysis to support the metabolic programming necessary for development (vol 41, pg 75, 2014)[J]. Immunity. 2018;49(2):375–6.PubMedPubMedCentral

74.

van der Windt GJW, Everts B, Chang C-H, Curtis JD, Freitas TC, Amiel E, et al. Mitochondrial respiratory capacity is a critical regulator of CD8(+) T cell memory development[J]. Immunity. 2012;36(1):68–78.PubMed

75.

Cogliati S, Frezza C, Soriano ME, Varanita T, Quintana-Cabrera R, Corrado M, et al. Mitochondrial cristae shape determines respiratory chain supercomplexes assembly and respiratory efficiency[J]. Cell. 2013;155(1):160–71.PubMedPubMedCentral

76.

Mishra P, Carelli V, Manfredi G, Chan DC. Proteolytic cleavage of opa1 stimulates mitochondrial inner membrane fusion and couples fusion to oxidative phosphorylation (vol 19, pg 630, 2014)[J]. Cell Metab. 2014;19(5):891–891.

77.

Bird L. T CELLS mitochondrial shape shifters[J]. Nature Rev Immunol. 2016;16(7):403.

78.

Acin-Perez R, Enriquez JA. The function of the respiratory supercomplexes: the plasticity model[J]. Biochimica Et Biophysica Acta-Bioenergetics. 2014;1837(4):444–50.

79.

Yu TZ, Robotham JL, Yoon Y. Increased production of reactive oxygen species in hyperglycemic conditions requires dynamic change of mitochondrial morphology[J]. Proc Natl Acad Sci USA. 2006;103(8):2653–8.PubMed

80.

Baixauli F, Acin-Perez R, Villarroya-Beltri C, Mazzeo C, Nunez-Andrade N, Gabande-Rodriguez E, et al. Mitochondrial respiration controls lysosomal function during inflammatory T cell responses[J]. Cell Metab. 2015;22(3):485–98.PubMedPubMedCentral

81.

Garaude J, Acin-Perez R, Martinez-Cano S, Enamorado M, Ugolini M, Nistal-Villan E, et al. Mitochondrial respiratory-chain adaptations in macrophages contribute to antibacterial host defense[J]. Nat Immunol. 2016;17(9):1037–45.PubMedPubMedCentral

82.

Xia Y, Chen S, Zeng S, Zhao Y, Zhu C, Deng B, et al. Melatonin in macrophage biology: current understanding and future perspectives[J]. J Pineal Res. 2019;66(2):e12547.PubMed

83.

Narendra DP, Jin SM, Tanaka A, Suen D-F, Gautier CA, Shen J, et al. PINK1 is selectively stabilized on impaired mitochondria to activate parkin[J]. Plos Biol. 2010;8(1):e1000298.PubMedPubMedCentral

84.

Deretic V, Levine B. Autophagy balances inflammation in innate immunity[J]. Autophagy. 2018;14(2):243–51.PubMedPubMedCentral

85.

Zhu L, Wang H, Wu Y, He Z, Qin Y, Shen Q. The autophagy level is increased in the synovial tissues of patients with active rheumatoid arthritis and is correlated with disease severity[J]. Mediators Inflamm. 2017;76:23145.

86.

Puleston DJ, Zhang H, Powell TJ, Lipina E, Sims S, Panse I, et al. Autophagy is a critical regulator of memory CD8(+) T cell formation[J]. Elife. 2014;3:e03706.PubMedCentral

87.

Zhao Y, Guo Y, Jiang Y, Zhu X, Liu Y, Zhang X. Mitophagy regulates macrophage phenotype in diabetic nephropathy rats[J]. Biochem Biophys Res Commun. 2017;494(1–2):42–50.PubMed

88.

Esteban-Martinez L, Sierra-Filardi E, McGreal RS, Salazar-Roa M, Marino G, Seco E, et al. Programmed mitophagy is essential for the glycolytic switch during cell differentiation[J]. EMBO J. 2017;36(12):1688–706.PubMedPubMedCentral

89.

Angajala A, Lim S, Phillips JB, Kim J-H, Yates C, You Z, et al. Diverse roles of mitochondria in immune responses: novel insights into immuno-metabolism[J]. Front Immunol. 2018;9:1605.PubMedPubMedCentral

90.

Mills EL, O'Neill LA. Reprogramming mitochondrial metabolism in macrophages as an anti-inflammatory signal[J]. Eur J Immunol. 2016;46(1):13–211.PubMed

91.

Shapiro H, Lutaty A, Ariel A. Macrophages, meta-Inflammation, and Immuno-metabolism[J]. Sci World J. 2011;11:2509–29.

92.

Beltran B, Mathur A, Duchen MR, Erusalimsky JD, Moncada S. The effect of nitric oxide on cell respiration: a key to understanding its role in cell survival or death[J]. Proc Natl Acad Sci USA. 2000;97(26):14602–7.PubMed

93.

Dubois RN, Abramson SB, Crofford L, Gupta RA, Simon LS, Van De Putte LBA, et al. Cyclooxygenase in biology and disease[J]. Faseb J. 1998;12(12):1063–73.PubMed

94.

Moon J-S, Lee S, Park M-A, Siempos II, Haslip M, Lee PJ, et al. UCP2-induced fatty acid synthase promotes NLRP3 inflammasome activation during sepsis[J]. J Clin Investig. 2015;125(2):665–80.PubMed

95.

Mills EL, Ryan DG, Prag HA, Dikovskaya D, Menon D, Zaslona Z, et al. Itaconate is an anti-inflammatory metabolite that activates Nrf2 via alkylation of KEAP1[J]. Nature. 2018;556(7699):113.PubMedPubMedCentral

96.

Michopoulos F, Karagianni N, Whalley NM, Firth MA, Nikolaou C, Wilson ID, et al. Targeted metabolic profiling of the Tg197 mouse model reveals itaconic acid as a marker of rheumatoid arthritis[J]. J Proteome Res. 2016;15(12):4579–90.PubMed

97.

Lampropoulou V, Sergushichev A, Bambouskova M, Nair S, Vincent EE, Loginicheva E, et al. Itaconate links inhibition of succinate dehydrogenase with macrophage metabolic remodeling and regulation of inflammation[J]. Cell Metab. 2016;24(1):158–66.PubMedPubMedCentral

98.

Murphy MP, O'Neill LAJ. Krebs cycle reimagined: the emerging roles of succinate and itaconate as signal transducers[J]. Cell. 2018;174(4):780–4.PubMed

99.

Mills E, O'Neill LAJ. Succinate: a metabolic signal inflammation[J]. Trends Cell Biol. 2014;24(5):313–20.PubMed

100.

Mills EL, Kelly B, Logan A, Costa ASH, Varma M, Bryant CE, et al. Succinate dehydrogenase supports metabolic repurposing of mitochondria to drive inflammatory macrophages[J]. Cell. 2016;167(2):457.PubMedPubMedCentral

101.

Saraiva AL, Veras FP, Peres RS, Talbot J, de Lima KA, Luiz JP, et al. Succinate receptor deficiency attenuates arthritis by reducing dendritic cell traffic and expansion of T(h)17 cells in the lymph nodes[J]. Faseb J. 2018;32(12):6550–8.

102.

Yadav SK, Soin D, Ito K, Dhib-Jalbut S. Insight into the mechanism of action of dimethyl fumarate in multiple sclerosis[J]. J Mol Med (Berlin, Germany). 2019;97(4):463–72.

103.

Yamaguchi Y, Kanzaki H, Katsumata Y, Itohiya K, Fukaya S, Miyamoto Y, et al. Dimethyl fumarate inhibits osteoclasts via attenuation of reactive oxygen species signalling by augmented antioxidation[J]. J Cell Mol Med. 2018;22(2):1138–47.PubMed

104.

Nishioku T, Kawamoto M, Okizono R, Sakai E, Okamoto K, Tsukuba T. Dimethyl fumarate prevents osteoclastogenesis by decreasing NFATc1 expression, inhibiting of erk and p38 MAPK phosphorylation, and suppressing of HMGB1 release[J]. Biochem Biophys Res Commun. 2020. https://doi.org/10.1016/j.bbrc.2020.05.088.CrossRefPubMed

105.

Kaminski MM, Sauer SW, Kaminski M, Opp S, Ruppert T, Grigaravicius P, et al. T cell activation is driven by an ADP-dependent glucokinase linking enhanced glycolysis with mitochondrial reactive oxygen species generation[J]. Cell Rep. 2012;2(5):1300–15.PubMed

106.

Mehta MM, Weinberg SE, Chandel NS. Mitochondrial control of immunity: beyond ATP[J]. Nat Rev Immunol. 2017;17(10):608–20.PubMed

107.

Gerriets VA, Kishton RJ, Nichols AG, Macintyre AN, Inoue M, Ilkayeva O, et al. Metabolic programming and PDHK1 control CD4(+) T cell subsets and inflammation[J]. J Clin Investig. 2015;125(1):194–207.PubMed

108.

Balmer ML, Ma EH, Bantug GR, Grahlert J, Pfister S, Glatter T, et al. Memory CD8(+) T cells require increased concentrations of acetate induced by stress for optimal function[J]. Immunity. 2016;44(6):1312–24.PubMed

109.

Gubser PM, Bantug GR, Razik L, Fischer M, Dimeloe S, Hoenger G, et al. Rapid effector function of memory CD8(+) T cells requires an immediate-early glycolytic switch[J]. Nature Immunol. 2013;14(10):1064.

110.

Okayyaocahtatyat K. Evaluation of tocilizumab therapy in patients with rheumatoid arthritis based on FDG-PET/CT[J]. BMC Musculoskelet Disord. 2014;15:393.

111.

Choi YH. ROS-mediated activation of AMPK plays a critical role in sulforaphane-induced apoptosis and mitotic arrest in AGS human gastric cancer cells[J]. Gen Physiol Biophys. 2018;37(2):129–40.PubMed

112.

Jeong HW, Hsu KC, Lee J-W, Ham M, Huh JY, Shin HJ, et al. Berberine suppresses proinflammatory responses through AMPK activation in macrophages[J]. Am J Physiol Endocrinol Metab. 2009;296(4):E955–E964964.PubMed

113.

Liu-Bryan R. Inflammation and intracellular metabolism: new targets in OA[J]. Osteoarthr Cartil. 2015;23(11):1835–42.PubMedPubMedCentral

114.

Liu TF, Brown CM, El Gazzar M, McPhail L, Millet P, Rao A, et al. Fueling the flame: bioenergy couples metabolism and inflammation[J]. J Leukoc Biol. 2012;92(3):499–507.PubMedPubMedCentral

115.

Gai L, Chu L, Xia R, Chen Q, Sun X. Barbaloin attenuates mucosal damage in experimental models of rat colitis by regulating inflammation and the AMPK signaling pathway[J]. Med Sci Monit. 2019;25:10045–56.PubMedPubMedCentral

116.

Sanadgol N, Barati M, Houshmand F, Hassani S, Clarner T, Shahlaei M, et al. Metformin accelerates myelin recovery and ameliorates behavioral deficits in the animal model of multiple sclerosis via adjustment of AMPK/Nrf2/mTOR signaling and maintenance of endogenous oligodendrogenesis during brain self-repairing period[J]. Pharmacol Rep. 2019;18:1–18.

117.

Samimi Z, Kardideh B, Zafari P, Bahrehmand F, Roghani SA, Taghadosi M. The impaired gene expression of adenosine monophosphate-activated kinase (AMPK), a key metabolic enzyme in leukocytes of newly diagnosed rheumatoid arthritis patients[J]. Mol Biol Rep. 2019;46(6):6353–60.PubMed

118.

Wen Z, Jin K, Shen Y, Yang Z, Li Y, Wu B, et al. N-myristoyltransferase deficiency impairs activation of kinase AMPK and promotes synovial tissue inflammation[J]. Nature Immunol. 2019;20(3):313.

119.

Jiang S, Park DW, Stigler WS, Creighton J, Ravi S, Darley-Usmar V, et al. Mitochondria and AMP-activated protein kinase-dependent mechanism of efferocytosis[J]. J Biol Chem. 2013;288(36):26013–26.PubMedPubMedCentral

120.

Carroll KC, Viollet B, Suttles J. AMPKalpha1 deficiency amplifies proinflammatory myeloid APC activity and CD40 signaling[J]. J Leukoc Biol. 2013;94(6):1113–21.PubMedPubMedCentral

121.

Guma M, Wang Y, Viollet B, Ru L-B. AMPK activation by A-769662 controls IL-6 expression in inflammatory arthritis[J]. PLoS ONE. 2015;10(10):e0140452.PubMedPubMedCentral

122.

Kang KY, Kim YK, Yi H, Kim J, Jung H-R, Kim IJ, et al. Metformin downregulates Th17 cells differentiation and attenuates murine autoimmune arthritis[J]. Int Immunopharmacol. 2013;16(1):85–92.PubMed

123.

Yan H, Zhou H-F, Hu Y, Pham CTN. Suppression of experimental arthritis through AMP-activated protein kinase activation and autophagy modulation[J]. J Rheum Dis Treat. 2015;1(1):5–5.PubMedPubMedCentral

124.

Zhou J, Yu Y, Yang X, Wang Y, Song Y, Wang Q, et al. Berberine attenuates arthritis in adjuvant-induced arthritic rats associated with regulating polarization of macrophages through AMPK/NF-кB pathway[J]. Eur J Pharmacol. 2019;852:179–88.PubMed

125.

Kim J, Guan K-L. mTOR as a central hub of nutrient signalling and cell growth[J]. Nat Cell Biol. 2019;21(1):63–71.PubMed

126.

Suto T, Karonitsch T. The immunobiology of mTOR in autoimmunity[J]. J Autoimmun. 2019;10:2373.

127.

Duevel K, Yecies JL, Menon S, Raman P, Lipovsky AI, Souza AL, et al. Activation of a metabolic gene regulatory network downstream of mTOR complex 1[J]. Mol Cell. 2010;39(2):171–83.

128.

Corcoran SE, O'Neill LAJ. HIF1 alpha and metabolic reprogramming in inflammation[J]. J Clin Investig. 2016;126(10):3699–707.PubMed

129.

Michalek RD, Gerriets VA, Jacobs SR, Macintyre AN, MacIver NJ, Mason EF, et al. Cutting edge: distinct glycolytic and lipid oxidative metabolic programs are essential for effector and regulatory CD4(+) T cell subsets[J]. J Immunol. 2011;186(6):3299–303.PubMedPubMedCentral

130.

Son HJ, Lee J, Lee SY, Kim EK, Park MJ, Kim KW, et al. Metformin attenuates experimental autoimmune arthritis through reciprocal regulation of Th17/Treg balance and osteoclastogenesis[J]. Mediators Inflamm. 2014;2014:973986.PubMedPubMedCentral

131.

Karonitsch T, Kandasamy RK, Kartnig F, Herdy B, Dalwigk K, Niederreiter B, et al. mTOR senses environmental cues to shape the fibroblast-like synoviocyte response to inflammation[J]. Cell Rep. 2018;23(7):2157–67.PubMedPubMedCentral

132.

Miao C-G, Xiong Y-Y, Qin M-S, Chen H, Chang J. Experimental Study on Paeoniflorin Inhibiting mTOR Signaling Pathway in Adjuvant Arthritis Rats[J]. Sichuan da xue xue bao. Yi xue ban = J Sichuan Univ Med Sci. 2018;49(4):535–9.

133.

Deng HM, Zheng M, Hu ZL, Zeng XP, Kuang NZ, Fu YY. Effects of daphnetin on the autophagy signaling pathway of fibroblast-like synoviocytes in rats with collagen-induced arthritis (CIA) induced by TNF-alpha[J]. Cytokine. 2020;127:154952.PubMed

134.

Jung YJ, Isaacs JS, Lee S, Trepel J, Neckers L. IL-1beta-mediated up-regulation of HIF-1alpha via an NFkappaB/COX-2 pathway identifies HIF-1 as a critical link between inflammation and oncogenesis[J]. FASEB. 2003;17(14):2115–7.

135.

Zhou J, Schmid T, Brune B. Tumor necrosis factor-alpha causes accumulation of a ubiquitinated form of hypoxia inducible factor-1alpha through a nuclear factor-kappaB-dependent pathway[J]. Mol Biol Cell. 2003;14(6):2216–25.PubMedPubMedCentral

136.

Bruning U, Fitzpatrick SF, Frank T, Birtwistle M, Taylor CT, Cheong A. NFkappaB and HIF display synergistic behaviour during hypoxic inflammation[J]. Cell Mol Life Sci CMLS. 2012;69(8):1319–29.PubMed

137.

Remels AHV, Gosker HR, Verhees KJP, Langen RCJ, Schols AMWJ. TNF-alpha-Induced NF-kappa B activation stimulates skeletal muscle glycolytic metabolism through activation of HIF-1 alpha[J]. Endocrinology. 2015;156(5):1770–811.PubMed

138.

Park SY, Lee SW, Kim HY, Lee WS, Hong KW, Kim CD. HMGB1 induces angiogenesis in rheumatoid arthritis via HIF-1alpha activation[J]. Eur J Immunol. 2015;45(4):1216–27.PubMed

139.

Oshea JJ. Jaks, STATs, cytokine signal transduction, and immunoregulation: are we there yet? (vol 7, pg 1, 1997)[J]. Immunity. 1997;7(3):U9–U9.

140.

Camporeale A, Demaria M, Monteleone E, Giorgi C, Wieckowski MR, Pinton P, et al. STAT3 activities and energy metabolism: dangerous liaisons[J]. Cancers. 2014;6(3):1579–96.PubMedPubMedCentral

141.

Gao W, McCormick J, Connolly M, Balogh E, Veale DJ, Fearon U. Hypoxia and STAT3 signalling interactions regulate pro-inflammatory pathways in rheumatoid arthritis[J]. Ann Rheum Dis. 2015;74(6):1275–83.PubMed

142.

McGarry T, Orr C, Wade S, Biniecka M, Wade S, Gallagher L, et al. JAK/STAT blockade alters synovial bioenergetics, mitochondrial function, and proinflammatory mediators in rheumatoid arthritis[J]. Arthritis Rheumatol. 2018;70(12):1959–70.PubMed

143.

Speirs C, Williams JJL, Riches K, Salt IP, Palmer TM. Linking energy sensing to suppression of JAK-STAT signalling: a potential route for repurposing AMPK activators?[J]. Pharmacol Res. 2018;128:88–100.PubMed

144.

Lai EC. Keeping a good pathway down: transcriptional repression of Notch pathway target genes by CSL proteins[J]. EMBO Rep. 2002;3(9):840–5.PubMedPubMedCentral

145.

Iso T, Kedes L, Hamamori Y. HES and HERP families: multiple effectors of the Notch signaling pathway[J]. J Cell Physiol. 2003;194(3):237–55.PubMed

146.

Iso T, Hamamori Y, Kedes L. Notch signaling in vascular development[J]. Arterioscler Thromb Vasc Biol. 2003;23(4):543–53.PubMed

147.

Gridley T. Notch signaling during vascular development[J]. Proc Natl Acad Sci USA. 2001;98(10):5377–8.PubMed

148.

Ho J, Uyttendaele H, Kitajewski J, Rossant J. A role for Notch signaling in vascular remodeling during endothelial development[J]. Pediatr Res. 2000;47(4):70A–.

149.

Gao W, Sweeney C, Connolly M, Kennedy A, Chin Teck N, McCormick J, et al. Notch-1 mediates hypoxia-induced angiogenesis in rheumatoid arthritis[J]. Arthritis Rheum. 2012;64(7):2104–13.PubMed

150.

Weinstein BM, Lawson ND. Arteries, veins, notch, and VEGF[J]. Cold Spring Harbor Symp Quantitative Biol. 2002;67:155–62.

151.

Karlsson C, Jonsson M, Asp J, Brantsing C, Kageyama R, Lindahl A. Notch and HES5 are regulated during human cartilage differentiation[J]. Cell Tissue Res. 2007;327(3):539–51.PubMed

152.

Diez H, Fischer A, Winkler A, Hu C-J, Hatzopoulos AK, Breier G, et al. Hypoxia-mediated activation of Dll4-Notch-Hey2 signaling in endothelial progenitor cells and adoption of arterial cell fate[J]. Exp Cell Res. 2007;313(1):1–9.PubMed

153.

Okano T, Saegusa J, Takahashi S, Ueda Y, Morinobu A. Immunometabolism in rheumatoid arthritis[J]. Immunol Med. 2018;41(3):89–97.PubMed

154.

Weyand CM, Goronzy JJ. Immunometabolism in the development of rheumatoid arthritis[J]. Immunol Rev. 2020;294(1):177–87.PubMed

155.

Shervington L, Darekar A, Shaikh M, Mathews R, Shervington A. Identifying reliable diagnostic/predictive biomarkers for rheumatoid arthritis[J]. Biomark Insights. 2018;13:1177271918801005.PubMedPubMedCentral

156.

Garcia-Carbonell R, Divakaruni AS, Lodi A, Vicente-Suarez I, Saha A, Cheroutre H, et al. Critical role of glucose metabolism in rheumatoid arthritis fibroblast-like synoviocytes[J]. Arthritis Rheumatol. 2016;68(7):1614–26.PubMedPubMedCentral

157.

Hoshino A, Hirst JA, Fujii H. Regulation of cell proliferation by interleukin-3-induced nuclear translocation of pyruvate kinase[J]. J Biol Chem. 2007;282(24):17706–11.PubMed

158.

Demaria M, Poli V. PKM2, STAT3 and HIF-1alpha: the Warburg's vicious circle[J]. Jak-Stat. 2012;1(3):194–6.PubMedPubMedCentral

159.

Zou Y, Zeng S, Huang M, Qiu Q, Xiao Y, Shi M, et al. Inhibition of 6-phosphofructo-2-kinase suppresses fibroblast-like synoviocytes-mediated synovial inflammation and joint destruction in rheumatoid arthritis[J]. Br J Pharmacol. 2017;174(9):893–908.PubMedPubMedCentral

160.

Carames B, Hasegawa A, Taniguchi N, Miyaki S, Blanco FJ, Lotz M. Autophagy activation by rapamycin reduces severity of experimental osteoarthritis[J]. Ann Rheum Dis. 2012;71(4):575–81.PubMed

Titel: Metabolic reprogramming as a key regulator in the pathogenesis of rheumatoid arthritis
verfasst von: Wei-wei Cai
Yun Yu
Shi-ye Zong
Fang Wei
Publikationsdatum: 14.08.2020
Verlag: Springer International Publishing
Erschienen in: Inflammation Research / Ausgabe 11/2020
Print ISSN: 1023-3830
Elektronische ISSN: 1420-908X
DOI: https://doi.org/10.1007/s00011-020-01391-5

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

17.05.2024 Herzinsuffizienz Nachrichten

Bei adipösen Patienten mit Herzinsuffizienz des HFpEF-Phänotyps ist Semaglutid von symptomatischem Nutzen. Resultiert dieser Benefit allein aus der Gewichtsreduktion oder auch aus spezifischen Effekten auf die Herzinsuffizienz-Pathogenese? Eine neue Analyse gibt Aufschluss.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Purpose

Methods

Results

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 11/2020

Correction to: Optimized THP-1 differentiation is required for the detection of responses to weak stimuli

Sleep deprivation aggravated lipopolysaccharide/d-galactosamine-induced acute liver injury by suppressing melatonin production

IL-33 deficiency protects mice from DSS-induced experimental colitis by suppressing ILC2 and Th17 cell responses

The pharmacological effects of inhaled cannabis on pain in patients with multiple sclerosis: risks versus rewards

Biochanin A impedes STAT3 activation by upregulating p38δ MAPK phosphorylation in IL-6-stimulated macrophages